Related Experiment Video
Updated: Jan 7, 2026

Whole-body PET/MRI of Pediatric Patients: The Details That Matter
Published on: December 19, 2017
Evaluating the Safety of Gastrointestinal Contrast Agents in Pediatric Patients: A Retrospective Study
Abdullah Alshehri1, Rayan Hejles2, Mohammad Aldaffaa3
1Pediatric Surgery, King Saud University, Riyadh, SAU.
Insights
Gastrointestinal contrast imaging is safe for infants and does not increase necrotizing enterocolitis (NEC) risk. Avoid hyperosmolar agents in active NEC cases.
Area of Science:
- Pediatric Radiology
- Neonatal Gastroenterology
- Clinical Safety Studies
Background:
- Gastrointestinal (GI) contrast imaging is a common diagnostic tool for pediatric patients.
- Concerns exist regarding potential adverse effects of contrast agents on the infant intestinal wall, especially in premature infants or those with inflammation.
- These concerns are largely based on anecdotal evidence and older animal research.
Purpose of the Study:
- To evaluate the association between GI contrast agent exposure and the incidence of necrotizing enterocolitis (NEC) within 30 days in infants.
- To address clinical uncertainties regarding the safety of GI contrast agents in vulnerable infant populations.
Main Methods:
- Retrospective study at a single tertiary care institution with a Level IV NICU.
- Included 245 infants who underwent GI contrast-enhanced radiological studies.
- Primary outcome: development of NEC within 30 days post-contrast exposure.
Main Results:
- Out of 245 infants, 15 (6.1%) had a prior NEC diagnosis over two weeks before imaging.
- One term newborn with suspected NEC experienced intestinal perforation after contrast exposure.
- No increased incidence of NEC was observed within 30 days of contrast agent administration.
Conclusions:
- GI contrast agent exposure appears safe for infants, including premature newborns, without elevating NEC risk within 30 days.
- Caution is advised, suggesting avoidance of hyperosmolar contrast agents in infants with active NEC.
- Further research may refine safety protocols for contrast use in neonatal GI imaging.
Background:
Gastrointestinal (GI) contrast imaging is commonly performed in pediatric patients to diagnose and treat various GI conditions. However, a widely held clinical belief suggests that contrast agents may have deleterious side effects on the intestinal wall, particularly in premature infants or those with pre-existing intestinal inflammation. This presumed risk is primarily supported by anecdotal reports and older animal studies.
Objective:
This study aimed to investigate the potential association between GI contrast agent exposure and the development of necrotizing enterocolitis (NEC) within a 30-day period in infants.
Materials And Methods:
A retrospective study was conducted at a single tertiary care institution with a level IV neonatal intensive care unit. All 245 infants who underwent any form of GI contrast-enhanced radiological study were included. The primary outcome was the development of NEC within 30 days following exposure to a contrast agent.
Results:
A total of 245 patients were included, of whom 15 (6.1%) had a documented history of NEC occurring more than two weeks prior to undergoing contrast imaging. Only one term newborn suspected of NEC progressed to intestinal perforation following contrast agent exposure.
Conclusion:
Our findings suggest that GI contrast agent exposure is generally safe in infants and does not increase the risk of NEC development within 30 days, including premature newborns. However, it may be safer to avoid hyperosmolar contrast agents in patients with active NEC.
Related Concept Videos
Imaging Studies III: Computed Tomography
Radiological Investigation I: X-ray and CT
Imaging Studies I: CT and MRI
Description of the Procedures
Computed Tomography (CT) scan:
Computed Tomography (CT) scans use X-ray technology to generate detailed images of bones, organs, and tissues. During the scan, the patient lies on a moving table...
Pharmacokinetics in Pediatric Patients: Drug Excretion
Imaging Studies for Cardiovascular System V: CT
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

